RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
Alnylam Pharmaceuticals, Inc. has announced that the European Patent Office (EPO) has ruled in favor of the Appellants in oral proceedings before the Board of Appeals related to the '623 (EP 1144623) patent in its Kreutzer-Limmer patent estate.
Intradigm Corporation has announced the issuance of United States patent 7,459,547, entitled "Methods and Compositions for Controlling Efficacy of RNA Silencing."
Small, specially designed bits of ribonucleic acid (RNA) can interfere with cholesterol metabolism, reducing harmful cholesterol by two-thirds in pre-clinical tests, according to a new study by researchers at UT Southwestern Medical Center in collaboration with Alnylam Pharmaceuticals and the Massachusetts Institute of Technology.
Roche (Basel) and Mirus Bio Corporation (Madison, WI, USA) announced today that they have entered into a definitive agreement under which Roche will acquire Mirus Bio Corporation, a privately-owned US company based in Madison, Wisconsin, that focuses on the discovery and development of innovative nucleic acid based technologies, including a proprietary RNAi (Ribonucleic Acid interference) delivery platform.
Roche and the US-based biopharmaceutical company Alnylam Pharmaceuticals, Inc. announced today that they have entered into a major alliance in which Roche obtains a non-exclusive license to Alnylam's technology platform for developing RNAi (RNA interference) therapeutics.
Two major drug companies have teamed up in order to develop a treatment for pandemic flu strains.
Sirna Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Sirna U.S. Patent No. 6,989,442 for the chemical synthesis and manufacturing of ribonucleic acids (RNA).
Benitec has announced an exclusive licensing deal with Stanford University. Under the license, Benitec receives exclusive rights to use the Minicircle DNA technology pioneered at Stanford University for all RNAi therapeutic uses, with sub-licensing rights.
Benitec Ltd. today announced the acquisition of Avocel, Inc. of Sunnyvale, CA, a leading RNAi therapeutics company, and the establishment of its wholly-owned US subsidiary, Benitec, Inc. Through the acquisition, Benitec gains its first in-house advanced therapeutic development program using DNA-directed RNAi (ddRNAi) to target the Hepatitis C virus.